Serum Uric Acid Levels and Onset of Cardiovascular Diseases: a CALIBER Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03425305|
Recruitment Status : Active, not recruiting
First Posted : February 7, 2018
Last Update Posted : February 7, 2018
|Condition or disease|
|Stable Angina Unstable Angina Myocardial Infarction Unheralded Coronary Heart Disease Death Heart Failure Cardiac Arrest Transient Ischaemic Attack Ischemic Stroke Subarachnoid Hemorrhage Intracerebral Hemorrhage Peripheral Arterial Disease Abdominal Aortic Aneurysm Atrial Fibrillation|
Smaller observational studies suggested that increased serum uric acid level is associated with increased incidence of several cardiovascular diseases. Associations with specific initial presentations of cardiovascular diseases have not been studied in large cohort from the general population, but may be of interest for use in risk prediction or to guide therapeutic strategies.
The aim of this study is to estimate associations between serum uric acid level and initial presentation of a range of cardiovascular diseases.
The study will use data from the CALIBER dataset of clinically collected electronic health record data from England. Patients enter the study when they have a blood urate measurement recorded in the dataset, and they are followed up until they experience one of the cardiovascular endpoints, death or transfer out of the participating primary care practice.
This study is part of the CALIBER (Clinical disease research using linked bespoke studies and electronic records) programme funded from the National Institute for Health Research (NIHR) and Wellcome Trust. The central theme of the CALIBER research is linkage of the Inpatient Hospital Episode Statistics (HES) with primary care (Clinical Practice Research Datalink) and other resources. The overarching aim of CALIBER is to better understand the aetiology and prognosis of specific coronary phenotypes across a range of causal domains, particularly where electronic records provide a contribution beyond traditional studies. CALIBER has received both Ethics approval (ref 09/H0810/16) and ECC approval (ref ECC 2-06(b)/2009 CALIBER dataset).
|Study Type :||Observational|
|Actual Enrollment :||180000 participants|
|Official Title:||Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study|
|Actual Study Start Date :||January 1998|
|Estimated Primary Completion Date :||February 2018|
|Estimated Study Completion Date :||February 2019|
- Initial presentation of cardiovascular diseases [ Time Frame: 15 years ]First recorded diagnosis of cardiovascular disease during follow-up: Stable angina, unstable angina, myocardial infarction, unheralded coronary heart disease death, heart failure, cardiac arrest/sudden cardiac death, transient ischaemic attack, ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage, peripheral arterial disease, abdominal aortic aneurysm, atrial fibrillation. We will identify the diagnoses using ICD-10 or Read codes in the linked data sources. Definitions for each endpoint are provided on the CALIBER data portal (https://www.caliberresearch.org/portal).
- All cause mortality [ Time Frame: 15 years ]